… We included patients with documented coronaryarterydisease (CAD) at baseline in FOURIER (n = 23,656) in these analyses. Patients were stratified based on the presence of residual …
Y Hao, Y Yang, Y Wang, J Li - International Heart Journal, 2022 - jstage.jst.go.jp
… 10 mg/day) or the evolocumab group (evolocumab 140 mg every 2 weeks combined with … We compared the blood lipid profiles, major adverse cardiovascularevents (MACEs), and …
… in Subjects With Elevated Risk (FOURIER) trial, in which 27 564 patients with atherosclerotic cardiovasculardisease treated with a statin were randomized to evolocumab vs placebo. …
… restoration of all clinicaloutcomes from the FOURIER trial is required. Meanwhile, clinicians should be sceptical about benefits versus harms of prescribing evolocumab for patients with …
… evolocumab significantly reduced cardiovascularevents in patients with atherosclerotic cardiovasculardisease and metabolic syndrome without an increase in serious safety events, …
K Oyama, RHM Furtado, A Fagundes Jr… - Journal of the American …, 2021 - jacc.org
… evolocumab to statin therapy in patients with established ASCVD reduces the risk of developing complex coronaryarterydisease … The benefits of evolocumab tended to increase over …
P Sever, I Gouni-Berthold, A Keech… - European journal of …, 2021 - academic.oup.com
… evolocumab by patient age and sex in the FOURIER trial, the first major cardiovascular outcome … blind trial, comparing evolocumab with placebo in 27,564 patients with atherosclerotic …
K Oyama, RP Giugliano, M Tang… - European Heart …, 2021 - academic.oup.com
… in patients with stable atherosclerotic cardiovasculardisease (ASCVD) on optimized statin therapy. 10 Evolocumab reduced major adverse cardiovascularevents in these patients, with …
… -kexin type 9) inhibitor evolocumab or placebo with a median … cardiovascularevents (MACE; a composite of cardiovascular … major coronary events (a composite of coronary heart death, …